PMID- 29196987
OWN - NLM
STAT- MEDLINE
DCOM- 20180130
LR  - 20180130
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 97
IP  - 1
DP  - 2018 Jan
TI  - Underweight status at diagnosis is associated with poorer outcomes in adult 
      patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
PG  - 73-81
LID - 10.1007/s00277-017-3156-x [doi]
AB  - Recent studies have described various impacts of obesity and being overweight on 
      acute myeloid leukemia (AML) outcomes in adult patients, but little is known 
      about the impact of being underweight. We compared the outcomes of underweight 
      patients to those of normal weight and overweight patients. Adult patients with 
      AML who registered in the JALSG AML201 study (n = 1057) were classified into 
      three groups: underweight (body mass index [BMI] < 18.5, n = 92), normal weight 
      (BMI 18.5-25, n = 746), and overweight (BMI >/= 25, n = 219). With the exception of 
      age and male/female ratio, patient characteristics were comparable among the 
      three groups. Rates of complete remission following induction chemotherapy were 
      similar among the three groups (p = 0.68). We observed a significant difference 
      in overall survival (OS), disease-free survival (DFS), and non-relapse mortality 
      (NRM) between underweight and normal weight patients (3-year OS 34.8 vs. 47.7%, 
      p = 0.01; DFS 28.6 vs. 39.8%, p = 0.02; 1-year NRM 6.2 vs. 2.6%, p = 0.05), but 
      not between underweight and overweight patients. In multivariate analysis, 
      underweight was an independent adverse prognostic factor for OS (p < 0.01), DFS 
      (p = 0.01), and NRM (p = 0.04). During the first induction chemotherapy, the 
      incidences of documented infection (DI) and severe adverse events (AEs) were 
      higher in underweight patients than those in normal weight patients (DI 16 vs. 
      8.1%, p = 0.04; AE 36 vs. 24%, p = 0.05). In conclusion, underweight was an 
      independent adverse prognostic factor for survival in adult AML patients.
FAU - Harada, Kaito
AU  - Harada K
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
FAU - Doki, Noriko
AU  - Doki N
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. 
      n-doki@cick.jp.
FAU - Hagino, Takeshi
AU  - Hagino T
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
FAU - Miyawaki, Shuichi
AU  - Miyawaki S
AD  - Division of hematology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan.
FAU - Ohtake, Shigeki
AU  - Ohtake S
AD  - Institute of Liberal Arts and Science, Kanazawa University, Kanazawa, Japan.
FAU - Kiyoi, Hitoshi
AU  - Kiyoi H
AD  - Department of Hematology and Oncology, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Miyazaki, Yasushi
AU  - Miyazaki Y
AD  - Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, 
      Nagasaki, Japan.
FAU - Fujita, Hiroyuki
AU  - Fujita H
AD  - Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan.
FAU - Usui, Noriko
AU  - Usui N
AD  - Division of Hematology and Oncology, Department of Internal Medicine, Jikei 
      University School of Medicine, Tokyo, Japan.
FAU - Okumura, Hirokazu
AU  - Okumura H
AD  - Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, 
      Japan.
FAU - Miyamura, Koichi
AU  - Miyamura K
AD  - Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, 
      Nagoya, Japan.
FAU - Nakaseko, Chiaki
AU  - Nakaseko C
AD  - Department of Hematology, Chiba University Hospital, Chiba, Japan.
FAU - Fujieda, Atsushi
AU  - Fujieda A
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine, Tsu, Japan.
FAU - Nagai, Tadashi
AU  - Nagai T
AD  - Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
FAU - Yamane, Takahisa
AU  - Yamane T
AD  - Department of Hematology, Osaka City General Hospital, Osaka, Japan.
FAU - Sakamaki, Hisashi
AU  - Sakamaki H
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
FAU - Ohnishi, Kazunori
AU  - Ohnishi K
AD  - Japanese Red Cross Aichi Blood Center, Seto, Japan.
FAU - Naoe, Tomoki
AU  - Naoe T
AD  - National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
FAU - Ohno, Ryuzo
AU  - Ohno R
AD  - Aichi Cancer Center, Nagoya, Japan.
FAU - Ohashi, Kazuteru
AU  - Ohashi K
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
LA  - eng
PT  - Journal Article
DEP - 20171202
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Body Mass Index
MH  - Body Weight/physiology
MH  - Female
MH  - Humans
MH  - Induction Chemotherapy
MH  - Leukemia, Myeloid, Acute/complications/*diagnosis/drug therapy/*mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Thinness/*complications/*mortality
MH  - Young Adult
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Adult
OT  - Body mass index
OT  - Underweight
EDAT- 2017/12/03 06:00
MHDA- 2018/01/31 06:00
CRDT- 2017/12/03 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/12/03 06:00 [pubmed]
PHST- 2018/01/31 06:00 [medline]
PHST- 2017/12/03 06:00 [entrez]
AID - 10.1007/s00277-017-3156-x [pii]
AID - 10.1007/s00277-017-3156-x [doi]
PST - ppublish
SO  - Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 
      2.